Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study

Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study

This retrospective cohort study evaluated characteristics, treatment patterns, and clinical outcomes in adults with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving first-line (1L) systemic treatment with or without avelumab 1L maintenance (1LM) between January 2020 and July 2023....

Full description

Saved in:
Bibliographic Details
Main Authors: Helen H. Moon, Chiemeka Ike, Ruth W. Dixon, Christopher L. Crowe, Malvika Venkataraman, Valerie Morris, Mairead Kearney, Ivy Tonnu-Mihara, John Barron
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Current Oncology
Subjects:
bladder cancer
first-line treatment
healthcare costs
immune checkpoint inhibitors
metastatic urothelial carcinoma
outcome assessment
Online Access:https://www.mdpi.com/1718-7729/32/7/384
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/7/384

Similar Items